Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation with Venetoclax, Hypomethylating Agents and DLI - a Retrospective Multi Center Study

Blood (2019) 134 (Supplement_1): 4563.

https://doi.org/10.1182/blood-2019-125087

Published: 2019

Journal Articles

Clinical Relevance of Somatic Mutations in Chronic Myelomonocytic Leukemia Undergoing Allogeneic Stem Cell Transplantation

Nico Gagelmann, Anita Badbaran, Rashit Bogdanov, PhD, Olivier Nibourel, Friedrich Stoelzel, MD, Christina Rautenberg, MD, Heiko Becker, MD, Aleksandar Radujkovic, MD, Michael Koldehoff, Prof, MD PhD, Maximilian Christopeit, PhD, Peter Dreger, Jürgen Finke, MD, Guido Kobbe, MD, Uwe Platzbecker, Marie Robin, MD, Dietrich W. Beelen, Nicolaus Kroeger, MD

Blood (2019) 134 (Supplement_1): 1713.

https://doi.org/10.1182/blood-2019-121969

Published: 2019

Journal Articles

Combined Retro- and Prospective Analysis of Adherence to Guidelines and Patient-Tailored Therapeutic Recommendations in Patients with Myelodysplastic Syndromes (MDS) at a Tertiary Care Centre

Annika Kasprzak, Kathrin Nachtkamp, MD, Mustafa Kondakci, MD, Thomas Schroeder, MD, Guido Kobbe, MD, Andrea Kündgen, MD, Jennifer Kaivers, MD, Christina Rautenberg, MD, Rainer Haas, MD, Norbert Gattermann, MD, Nicolas Bonadies, MD, Ulrich Germing, MD

Blood (2019) 134 (Supplement_1): 4250.

https://doi.org/10.1182/blood-2019-124512

Published: 2019

Journal Articles

Impact of Somatic Mutations and Pretransplant Strategies on the Outcome of Patients Allografted for MDS or Secondary AML

Christina Rautenberg, MD, Stefanie Stepanow, Michael Lauseker, Ulrich Germing, MD, Paul Jäger, Stefanie Geyh, Esther Schuler, Karl Köhrer, Norbert Gattermann, MD, Rainer Haas, MD, Guido Kobbe, MD, Thomas Schroeder, MD

Blood (2019) 134 (Supplement_1): 4612.

https://doi.org/10.1182/blood-2019-126565

Published: 2019

Journal Articles

WT1 mRNA Expression in the Peripheral Blood of Patients with MDS Yields Additional Prognostic Information within the IPSS-R Risk Categories "Very Low", "Low" and "Intermediate"

Christina Rautenberg, MD, Sabrina Pechtel, Norbert Gattermann, MD, Rainer Haas, MD, Ulrich Germing, MD, Guido Kobbe, Thomas Michael Schroeder, MD PhD

Blood (2018) 132 (Supplement 1): 1827.

https://doi.org/10.1182/blood-2018-99-113524

Published: 2018

Journal Articles

Treatment of MDS, AML and CMML Relapse after Allogeneic Blood Stem Cell Transplantation with Azacitidine, Lenalidomide and Donor Lymphocyte Infusions Results from the Second Interim Analysis of the Prospective Azalena-Trial (NCT02472691)

Thomas Michael Schroeder, MD PhD, Christina Rautenberg, MD, Max Christopeit, Matthias Stelljes, MD, Eva Schmidt, Christoph Groth, MD, Christoph Scheid, MD, Udo Holtick, MD PhD, Stefan A Klein, MD, Dietrich W. Beelen, Kathrin Nachtkamp, MD, Rainer Haas, MD, Ulrich Germing, MD, Nicolaus Kröger, MD, Guido Kobbe

Blood (2018) 132 (Supplement 1): 703.

https://doi.org/10.1182/blood-2018-99-113776

Published: 2018

Journal Articles

Quantitative Next-Generation Sequencing (NGS) Based Monitoring of Minimal Residual Disease (MRD) Predicts Imminent Relapse in Patients with Myeloid Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation

Christina Rautenberg, MD, Beate Betz, Dagmar Wieczorek, Barbara Hildebrandt, Kathrin Nachtkamp, MD, Esther Schuler, Norbert Gattermann, MD, Guido Kobbe, MD, Rainer Haas, MD, Thomas Schroeder, MD

Blood (2017) 130 (Supplement 1): 2005.

https://doi.org/10.1182/blood.V130.Suppl_1.2005.2005

Published: 2017

Journal Articles

Treatment of Relapse of MDS, AML and CMML after Allogeneic Blood Stem Cell Transplantation with Azacitidine, Lenalidomide and Donor Lymphocyte Infusions - Results from the First Interim Analysis of the Azalena-Trial (NCT02472691)

Thomas Schroeder, MD, Christina Rautenberg, MD, Max Christopeit, Matthias Stelljes, MD, Eva Schmidt, Stefan Klein, MD, Christof Scheid, MD, Dietrich W Beelen, MD PhD, Kathrin Nachtkamp, MD, Rainer Haas, MD, Ulrich Germing, MD, Nicolaus Kröger, Guido Kobbe, MD

Blood (2017) 130 (Supplement 1): 4521.

https://doi.org/10.1182/blood.V130.Suppl_1.4521.4521

Published: 2017

Journal Articles

Decitabine As Salvage Therapy for Relapse of AML and MDS after Allogeneic Stem Cell Transplantation - a Retrospective Multicenter Analysis on Behalf of the German Cooperative Transplant Study Group

Thomas Schroeder, MD, Christina Rautenberg, MD, William Hermann Krüger, MD PhD, Uwe Platzbecker, MD, Gesine Bug, MD, Steinmann Juliane, Stefan A. Klein, MD, Olaf Hopfer, Kathrin Nachtkamp, MD, Ariane Dienst, MD, Mustafa Kondakci, MD, Pia Verena Schmidt, MD, Claudia Heyn, MD, Rainer Haas, MD, Ulrich Germing, Martin Bornhäuser, MD, Guido Kobbe, MD

Blood (2016) 128 (22): 3446.

https://doi.org/10.1182/blood.V128.22.3446.3446

Published: 2016

Journal Articles

Comparison Between Wilms' Tumor 1 (WT1) Expression Using a Standardized European Leukemia Net (ELN)-Certified Assay and Other Methods for Detection of Minimal Residual Disease (MRD) in MDS and AML Patients after Allogeneic Blood Stem Cell Transplantation

Christina Rautenberg, MD, Sabrina Pechtel, Barbara Hildebrandt, Beate Betz, Ariane Dienst, MD, Kathrin Nachtkamp, MD, Stefanie Geyh, Pia Verena Schmidt, MD, Claudia Heyn, MD, Mustafa Kondakci, MD, Norbert Gattermann, MD, Rainer Haas, MD, Ulrich Germing, Guido Kobbe, MD, Thomas Schroeder, MD

Blood (2016) 128 (22): 3447.

https://doi.org/10.1182/blood.V128.22.3447.3447

Published: 2016

NARROW

Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation with Venetoclax, Hypomethylating Agents and DLI - a Retrospective Multi Center Study

Clinical Relevance of Somatic Mutations in Chronic Myelomonocytic Leukemia Undergoing Allogeneic Stem Cell Transplantation

Combined Retro- and Prospective Analysis of Adherence to Guidelines and Patient-Tailored Therapeutic Recommendations in Patients with Myelodysplastic Syndromes (MDS) at a Tertiary Care Centre

Impact of Somatic Mutations and Pretransplant Strategies on the Outcome of Patients Allografted for MDS or Secondary AML

WT1 mRNA Expression in the Peripheral Blood of Patients with MDS Yields Additional Prognostic Information within the IPSS-R Risk Categories "Very Low", "Low" and "Intermediate"

Treatment of MDS, AML and CMML Relapse after Allogeneic Blood Stem Cell Transplantation with Azacitidine, Lenalidomide and Donor Lymphocyte Infusions Results from the Second Interim Analysis of the Prospective Azalena-Trial (NCT02472691)

Quantitative Next-Generation Sequencing (NGS) Based Monitoring of Minimal Residual Disease (MRD) Predicts Imminent Relapse in Patients with Myeloid Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation

Treatment of Relapse of MDS, AML and CMML after Allogeneic Blood Stem Cell Transplantation with Azacitidine, Lenalidomide and Donor Lymphocyte Infusions - Results from the First Interim Analysis of the Azalena-Trial (NCT02472691)

Decitabine As Salvage Therapy for Relapse of AML and MDS after Allogeneic Stem Cell Transplantation - a Retrospective Multicenter Analysis on Behalf of the German Cooperative Transplant Study Group

Comparison Between Wilms' Tumor 1 (WT1) Expression Using a Standardized European Leukemia Net (ELN)-Certified Assay and Other Methods for Detection of Minimal Residual Disease (MRD) in MDS and AML Patients after Allogeneic Blood Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only